The last patient in IBT's global phase 3 clinical program "The Connection Study" has finished treatment. IBP-9414 is being developed to prevent serious diseases in premature infants. The study evaluates the safety and clinical efficacy of IBP-9414.

As planned, the work to generate the results is underway. This marks the achievement of another important milestone in the largest randomized controlled study ever conducted on premature infants. It means that the clinical development program is now complete and the next milestone will be to generate the study's results.

The study involved 2,158 premature infants in 10 countries at approximately 100 hospitals.